German hospitals blast quality institute over stem cell therapy move:
This article was originally published in Clinica
Executive Summary
The German healthcare HTA body IQWiG (healthcare quality and economy institute), the executive arm of the G-BA reimbursement decision-making body, has come under fire from the national hospitals federation (DKG) over a negative recommendation on stem cell therapy in acute leukaemia cases. DKG president Dr Rudolf Kosters disagreed with the recommendation, delivered in a report in June 4, saying that IQWiG's methodology was not suited to this type of decision-making, that the G-BA should not base action on the recommendation pending further consultation, and that it is counter to established scientific knowledge. The report would doubtless provoke major concerns among seriously ill patients, he said, adding that transplant centres need to be able to implement the highest standards of care.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.